Fig. 3.
Effect of NMDAR glycine-site agonists on motor symptoms (tardive dyskinesia) as reflected in Abnormal Involuntary Movement Scale (AIMS) score. Data are from studies of glycine 74 75 or D-serine. 76 77 Across all studies, D-serine treatment led to a highly significant (t = 4.86, df = 192, P < .00001, d = .83) improvement in AIMS symptom, suggesting benefit of NMDAR agonist on motor and neuropsychological symptoms in schizophrenia.